3 results
See protocol page 19The primary objective is to determine the occurrence of post-operative AT/AF between the start of anesthesia and the first 5 days after CABG surgery in randomized groups, defined as patients in the SCS group and patient in the…
Primary Objective•*To evaluate the relative oral bioavailability of SMV, ODV, and AL-335 when administered as different concept fixed-dose combination (FDC) formulations compared to the single agents when administered together, all under fed…
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)